AbbVie said that the heavily-advertised drug was now approved for four conditions across different so-called “immune-mediated” inflammatory diseases.
AbbVie says FDA approves Skyrizi for ulcerative colitis
Read Next
- RBI tanked up on dollars in H2FY25, ahead of rupee’s fall in oct-Nov, ET BFSI
- Binance Futures to Launch SLERFUSDT and SCRTUSDT Contracts with Up to 75x Leverage
- Ukraine says Russia launched an intercontinental missile
- People who are often brought to tears by music tend to have these 8 traits
- TGL New York Golf Club brings on Eli Manning, Derek Jeter as investors
- Public.com makes margin investing available to its clients
- Private consumption back, driving domestic demand: RBI Bulletin, ET BFSI
